<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482648</url>
  </required_header>
  <id_info>
    <org_study_id>BBT401-UC-US01</org_study_id>
    <nct_id>NCT03482648</nct_id>
  </id_info>
  <brief_title>First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Novel Oral Peptide BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bridge Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRN Research, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bridge Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1&#xD;
      study is to assess the safety and tolerability of single and multiple ascending oral doses of&#xD;
      BBT-401-1S in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">October 3, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days after the last dose</time_frame>
    <description>To assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess Cmax of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess AUC of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) under fed conditions</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess Cmax of single oral dose under fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) under fed conditions</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>To assess AUC of single oral dose under fed conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-401-1S, Single dose</intervention_name>
    <description>Single dose of BBT-401-1S, 7 dose levels, oral capsule</description>
    <arm_group_label>Single Ascending Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-401-1S, Multiple doses</intervention_name>
    <description>Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule</description>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to BBT-401-1S, oral capsule</description>
    <arm_group_label>Multiple Ascending Doses</arm_group_label>
    <arm_group_label>Single Ascending Doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of&#xD;
             age, inclusive, at screening.&#xD;
&#xD;
          2. Continuous non-smoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to the first dose and throughout the study.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) at screening and weight ≥ 50 kg at&#xD;
             screening.&#xD;
&#xD;
          4. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI.&#xD;
&#xD;
          5. No clinically significant history or presence of ECG findings as judged by the PI or&#xD;
             qualified designee at screening and check-in.&#xD;
&#xD;
          6. For a female, must be of non-childbearing potential and therefore must have undergone&#xD;
             one of the following sterilization procedures, at least 6 months prior to the first&#xD;
             dose:&#xD;
&#xD;
               1. hysteroscopic sterilization;&#xD;
&#xD;
               2. bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               3. hysterectomy;&#xD;
&#xD;
               4. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year&#xD;
                  prior to the first dose and follicle-stimulating hormone (FSH) serum levels&#xD;
                  consistent with postmenopausal status as per PI judgment.&#xD;
&#xD;
          7. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain&#xD;
             from sexual intercourse during the study until 90 days beyond the last dose of study&#xD;
             drug. (No restrictions are required for a vasectomized male provided his vasectomy has&#xD;
             been performed 4 months or more prior to the first dose of study drug. A male who has&#xD;
             been vasectomized less than 4 months prior to the first dose must follow the same&#xD;
             restrictions as a non-vasectomized male).&#xD;
&#xD;
          8. If male, must agree to not donate sperm from the first dose until 90 days after&#xD;
             dosing.&#xD;
&#xD;
          9. Must have the ability to understand and sign a written informed consent form, which&#xD;
             must be obtained prior to initiation of study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is mentally or legally incapacitated or has significant emotional problems at&#xD;
             the time of the screening visit or expected during the conduct of the study.&#xD;
&#xD;
          2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI.&#xD;
&#xD;
          3. History of any illness that, in the opinion of the PI, might confound the results of&#xD;
             the study or poses an additional risk to the subject by their participation in the&#xD;
             study.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years prior to the&#xD;
             first dose or regular alcohol consumption within 6 months prior to the first dose with&#xD;
             an average weekly intake of greater than 21 glasses/units per week for males or 14&#xD;
             glasses/units per week for females, with one unit = 150 mL of wine or 360 mL of beer&#xD;
             or 45 mL of 45% alcohol.&#xD;
&#xD;
          5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s)&#xD;
             or related compounds.&#xD;
&#xD;
          6. History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          7. Active or latent tuberculosis.&#xD;
&#xD;
          8. Estimated creatinine clearance &lt;80 mL/min at screening.&#xD;
&#xD;
          9. Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total&#xD;
             and direct) &gt; ULN.&#xD;
&#xD;
         10. Absolute neutrophil count &lt; 1500 cells/mm3.&#xD;
&#xD;
         11. White blood cell count &lt; 3500 cells/mm3.&#xD;
&#xD;
         12. Haemoglobin levels &lt; 0.5 mg/dL below the lower limit of normal.&#xD;
&#xD;
         13. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
         14. Female subjects of childbearing potential.&#xD;
&#xD;
         15. Female subjects who are pregnant or lactating.&#xD;
&#xD;
         16. Positive urine drug or alcohol results at screening or check-in.&#xD;
&#xD;
         17. Positive urine cotinine at screening.&#xD;
&#xD;
         18. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg), or hepatitis C antibodies (HCV).&#xD;
&#xD;
         19. Unable to refrain from or anticipates the use of any drug, including prescription and&#xD;
             non-prescription medications, herbal remedies, or vitamin supplements beginning&#xD;
             approximately 14 days prior to the first dose and throughout the study.. Hormone&#xD;
             replacement therapy will not be allowed. After first dosing, acetaminophen (up to 2 g&#xD;
             per 24 hours) may be administered at the discretion of the PI or designee.&#xD;
&#xD;
         20. Has been on a diet incompatible with the on-study diet, in the opinion of the PI,&#xD;
             within the 28 days prior to the first dose and throughout the study.&#xD;
&#xD;
         21. Donation of blood or significant blood loss within 56 days prior to the first dose.&#xD;
&#xD;
         22. Plasma donation within 7 days prior to the first dose.&#xD;
&#xD;
         23. Exposure to more than four new chemical entities within 12 months prior to first&#xD;
             dosing day.&#xD;
&#xD;
         24. The subject has participated in a clinical trial and has received an investigational&#xD;
             product within 30 days, or 5 half-lives of the investigational product (whichever is&#xD;
             longer) of the first dose of study drug in the current study.&#xD;
&#xD;
         25. Any condition or circumstance, in the opinion of the PI, which may make the subject&#xD;
             unlikely to complete the study or comply with study procedures and requirements, or&#xD;
             may pose a risk to the subject's safety.&#xD;
&#xD;
         26. Subject has recent history (within 2 weeks of Day -1) of less than 1 bowel movement&#xD;
             every 2 days.&#xD;
&#xD;
         27. Subject has recent history (within 2 weeks of Day -1) of abnormal bowel movements,&#xD;
             such as diarrhea, loose stools, or constipation.&#xD;
&#xD;
             Stage 1 Only:&#xD;
&#xD;
         28. Is lactose intolerant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pellino-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

